We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
-0.09%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$235M
AUM Growth
+$87.8M
(+60%)
Cap. Flow
+$81.1M
Cap. Flow
% of AUM
34.53%
Top 10 Holdings %
Top 10 Hldgs %
9.76%
Holding
779
New
236
Increased
178
Reduced
104
Closed
257
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.52M |
| 2 |
Keurig Dr Pepper
KDP
|
+$2.4M |
| 3 |
Wells Fargo
WFC
|
+$2.19M |
| 4 |
AET
Aetna Inc
AET
|
+$2.17M |
| 5 |
PNC Financial Services
PNC
|
+$2.15M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Halliburton
HAL
|
+$1.39M |
| 2 |
Eaton
ETN
|
+$1.38M |
| 3 |
CB
CHUBB CORPORATION
CB
|
+$1.35M |
| 4 |
XEC
CIMAREX ENERGY CO
XEC
|
+$1.32M |
| 5 |
DaVita
DVA
|
+$1.26M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.9% |
| 2 | Consumer Discretionary | 14.51% |
| 3 | Industrials | 13.73% |
| 4 | Financials | 13.03% |
| 5 | Healthcare | 10.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BLUE
376
DELISTED
bluebird bio
BLUE
| $108K | 0.05% |
+196
| New | +$120K |
|
377
Madison Square Garden
MSGS
$9.59B
| $108K | 0.05% |
907
+280
| +45% | +$31.2K |
|
|
SEE
378
DELISTED
Sealed Air
SEE
| $108K | 0.05% |
2,243
-6,900
| -75% | -$302K |
|
379
Xerox
XRX
$345M
| $108K | 0.05% |
3,678
-25,806
| -88% | -$665K |
|
|
IDTI
380
DELISTED
Integrated Device Technology I
IDTI
| $108K | 0.05% |
5,263
-1,648
| -24% | -$34.6K |
|
381
Western Union
WU
$2.53B
| $105K | 0.04% |
+5,453
| New | +$98.1K |
|
|
NE
382
DELISTED
Noble Corporation
NE
| $105K | 0.04% |
10,101
-2,190
| -18% | -$19.9K |
|
383
AngloGold Ashanti
AU
$39.4B
| $104K | 0.04% |
7,600
+2,200
| +41% | +$23.8K |
|
384
CNO Financial Group
CNO
$4.94B
| $102K | 0.04% |
+5,700
| New | +$99.2K |
|
|
MDRX
385
DELISTED
Veradigm Inc. Common Stock
MDRX
| $102K | 0.04% |
+7,700
| New | +$101K |
|
|
ADPT
386
DELISTED
Adeptus Health Inc
ADPT
| $101K | 0.04% |
+1,815
| New | +$93.9K |
|
387
Portland General Electric
POR
$5.82B
| $99K | 0.04% |
2,500
-4,100
| -62% | -$157K |
|
388
Ziff Davis
ZD
$2B
| $99K | 0.04% |
+1,840
| New | +$111K |
|
|
RSPP
389
DELISTED
RSP Permian, Inc.
RSPP
| $99K | 0.04% |
3,400
+1,100
| +48% | +$25.8K |
|
|
WFT
390
DELISTED
Weatherford International plc
WFT
| $98K | 0.04% |
+12,611
| New | +$85.1K |
|
391
Restaurant Brands International
QSR
$26.2B
| $97K | 0.04% |
2,500
-1,300
| -34% | -$45.2K |
|
392
World Kinect Corp
WKC
$2.06B
| $97K | 0.04% |
+2,000
| New | +$85.8K |
|
|
KITE
393
DELISTED
Kite Pharma, Inc.
KITE
| $97K | 0.04% |
+2,117
| New | +$103K |
|
394
Huntington Ingalls Industries
HII
$11B
| $96K | 0.04% |
+700
| New | +$91.1K |
|
395
Aflac
AFL
$65.5B
| $95K | 0.04% |
3,000
-22,800
| -88% | -$677K |
|
396
JPMorgan Chase
JPM
$916B
| $95K | 0.04% |
+1,600
| New | +$93.4K |
|
397
Magna International
MGA
$18.8B
| $95K | 0.04% |
2,200
-6,000
| -73% | -$223K |
|
398
Viatris
VTRS
$20.8B
| $95K | 0.04% |
+2,045
| New | +$98.7K |
|
|
JUNO
399
DELISTED
Juno Therapeutics, Inc.
JUNO
| $95K | 0.04% |
2,501
+600
| +32% | +$20.9K |
|
|
JOY
400
DELISTED
Joy Global Inc
JOY
| $95K | 0.04% |
+5,901
| New | +$74.3K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q1 2016 Portfolio in Review
As of Q1 2016, Seven Eight Capital held 779 positions worth $235M, up 60% from $147M the previous quarter. Its ten largest holdings account for 9.8% of the portfolio.
Seven Eight Capital deployed $81.1M of net new capital in Q1 2016, opening 236 new positions and adding to 178 existing holdings. Its largest new stake was Allergan plc: 8,800 shares worth $2.36M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 12% a quarter earlier, followed by Consumer Discretionary and Industrials.
On the sell side, the largest reduction was Gilead Sciences, an estimated $884K trimmed.
- Seven Eight Capital's largest Q1 2016 buy was Allergan plc: 8,800 shares worth $2.36M.
- Seven Eight Capital added most to Wells Fargo in Q1 2016, an estimated $2.19M increase.
- Seven Eight Capital's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $884K.
- Seven Eight Capital fully exited Halliburton in Q1 2016, selling an estimated $1.39M.
- Seven Eight Capital's ten largest holdings make up 9.8% of its $235M portfolio in Q1 2016.
- Seven Eight Capital opened 236 new positions and closed 257 in Q1 2016.
- Seven Eight Capital's portfolio value rose 60% quarter-over-quarter to $235M.
Based on Seven Eight Capital's 13F filing for Q1 2016, filed 16 May 2016.